Skip to content
Triangle logo TriangleGet started
← Study library

NCT01706666 · REGISTRY CONDITION SEARCH

Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2018-09-17

This randomized phase II trial studies how well giving bortezomib with or without combination chemotherapy works as consolidation therapy in patients with newly diagnosed multiple myeloma who have completed stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, dexamethasone, and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving bortezomib is more effective with or without combination chemotherapy in the post transplant setting.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Proportion of Patients Experiencing a Stringent Complete Response (sCR) After 12 Cycles, 24 Months

→

outcome · POSTED

Survival Time

→

outcome · POSTED

Progression-free Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Creatinine =\< 2 mg/dL * Absolute neutrophil count (ANC) \>= 1000/mm\^3 * Platelet count \>= 75000/mm\^3 * Hemoglobin \>= 8.0 g/dL * Total bilirubin =\< 1.5 x upper limit of normal (ULN) * Treated myeloma: Prior induction therapy (any) and followed by autologous stem cell transplantation * Measurable disease at initial diagnosis, pre-stem cell transplant (SCT) or post-SCT of multiple myeloma as defined by at least ONE of the following: * Serum monoclonal protein \>= 0.5 g/dL * \> 200 mg of monoclonal protein in the urine on 24 hour electrophoresis * Serum immunoglobulin free light chain \>= 5 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio * Monoclonal bone marrow plasmacytosis \>= 30% (evaluable disease) * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2 * \< 120 days post SCT with no evidence of relapse or progression prior to registration * Provide voluntary informed written consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care * Negative serum pregnancy test done =\< 7 days prior to registration, for women of childbearing potential only * Willing to return to enrolling institution for follow-up during the active monitoring phase of the study * Ability to complete questionnaire(s) by themselves or with assistance * Female patients who: * Are postmenopausal for at least 1 year before the screening visit, OR * Are surgically sterile, OR * If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 30 days after the last dose of study treatment, OR agree to completely abstain from heterosexual intercourse * Male patients, even if surgically sterilized (ie, status postvasectomy), who: * Agree to practice effective barrier contraception during the entire study treatment period and through 30 days after the last dose of study treatment, OR * Agree to completely abstain from heterosexual intercourse Exclusion Criteria: * Other active malignancy =\< 3 years prior to registration; EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer * Other co-morbidity which would interfere with patient's ability to participate in trial, e.g. uncontrolled infection, uncompensated heart or lung disease * Other concurrent chemotherapy, radiotherapy, or any ancillary therapy considered investigational; NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment * Known to be human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus positive (HBV+) * Hypersensitivity to study drugs, boron or mannitol * Patient refractory to bortezomib (defined as patients who progressed while on bortezomib or within 60 days of receiving bortezomib) * Any serious medical or psychiatric condition that would prevent the subject from complying with the protocol treatment and procedures * Grade \>= 2 peripheral neuropathy * Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities; prior to study entry, any electrocardiogram (ECG) abnormality at screening must be documented by the investigator as not medically relevant * Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial * Radiation therapy within 3 weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy * Female patients who are lactating or pregnant
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive bortezomib SC on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.
    intervention Names
    1. Drug: bortezomib
    2. Other: laboratory biomarker analysis
    3. Procedure: quality-of-life assessment
    label
    Arm A (bortezomib)
    type
    EXPERIMENTAL
  2. description
    Patients receive bortezomib SC as in Arm A, cyclophosphamide PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24, and dexamethasone PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.
    intervention Names
    1. Drug: bortezomib
    2. Drug: cyclophosphamide
    3. Other: laboratory biomarker analysis
    4. Drug: dexamethasone
    5. Procedure: quality-of-life assessment
    label
    Arm B (bortezomib, cyclophosphamide, dexamethasone)
    type
    EXPERIMENTAL
  3. description
    Patients receive bortezomib SC as in Arm A and lenalidomide PO QD on days 1-28.
    intervention Names
    1. Drug: bortezomib
    2. Drug: lenalidomide
    3. Other: laboratory biomarker analysis
    4. Procedure: quality-of-life assessment
    label
    Arm C (bortezomib, lenalidomide)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm A (bortezomib)
    2. Arm B (bortezomib, cyclophosphamide, dexamethasone)
    3. Arm C (bortezomib, lenalidomide)
    description
    Given SC
    name
    bortezomib
    other Names
    1. LDP 341
    2. MLN341
    3. VELCADE
    type
    DRUG
  2. arm Group Labels
    1. Arm B (bortezomib, cyclophosphamide, dexamethasone)
    description
    Given PO
    name
    cyclophosphamide
    other Names
    1. CPM
    2. CTX
    3. Cytoxan
    4. Endoxan
    5. Endoxana
    type
    DRUG
  3. arm Group Labels
    1. Arm C (bortezomib, lenalidomide)
    description
    Given PO
    name
    lenalidomide
    other Names
    1. CC-5013
    2. IMiD-1
    3. Revlimid
    type
    DRUG
  4. arm Group Labels
    1. Arm A (bortezomib)
    2. Arm B (bortezomib, cyclophosphamide, dexamethasone)
    3. Arm C (bortezomib, lenalidomide)
    description
    Correlative studies
    name
    laboratory biomarker analysis
    type
    OTHER
  5. arm Group Labels
    1. Arm B (bortezomib, cyclophosphamide, dexamethasone)
    description
    Given PO
    name
    dexamethasone
    other Names
    1. Aeroseb-Dex
    2. Decaderm
    3. Decadron
    4. DM
    5. DXM
    type
    DRUG
  6. arm Group Labels
    1. Arm A (bortezomib)
    2. Arm B (bortezomib, cyclophosphamide, dexamethasone)
    3. Arm C (bortezomib, lenalidomide)
    description
    Ancillary studies
    name
    quality-of-life assessment
    other Names
    1. quality of life assessment
    type
    PROCEDURE
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
3
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Estimated by the number of sCRs divided by the total number of evaluable patients in each arm. Exact binomial confidence intervals for the true sCR rate will be calculated by arm. Stringent complete response (sCR) is defined as a complete response plus normal serum free light chain ratio and the absence of clonal cells in bone marrow by flow cytometry.
    measure
    Proportion of Patients Experiencing a Stringent Complete Response (sCR) After 12 Cycles, 24 Months
    time Frame
    24 months
secondary Outcomes
  1. description
    The distribution of survival time will be estimated by arm using the method of Kaplan-Meier.
    measure
    Survival Time
    time Frame
    From registration to death due to any cause, assessed up to 3 years
  2. description
    The distribution of progression-free survival will be estimated by arm using the method of Kaplan-Meier.
    measure
    Progression-free Survival
    time Frame
    From registration to the earliest date of documentation of disease progression or death due to any cause, assessed up to 3 years
Full study description
brief Summary
This randomized phase II trial studies how well giving bortezomib with or without combination chemotherapy works as consolidation therapy in patients with newly diagnosed multiple myeloma who have completed stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, dexamethasone, and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving bortezomib is more effective with or without combination chemotherapy in the post transplant setting.
detailed Description
PRIMARY OBJECTIVES: I. To compare the stringent complete response (sCR) rate after 12 cycles among arms. SECONDARY OBJECTIVES: I. To compare progression-free and overall survival among arms. II. To describe the adverse event profile of each arm. TERTIARY OBJECTIVES: I. To compare sCR after 6 cycles and 24 cycles and quality of life among arms. OUTLINE: Patients are randomized to 1 of 3 treatment arms. ARM A: Patients receive bortezomib subcutaneously (SC) on days 1 and 15 of courses 1-12 and day 1 of courses 13-24. ARM B: Patients receive bortezomib SC as in Arm A, cyclophosphamide orally (PO) on days 1 and 15 of courses 1-12 and day 1 of courses 13-24, and dexamethasone PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24. ARM C: Patients receive bortezomib SC as in Arm A and lenalidomide PO once daily (QD) on days 1-28. In all arms, treatment continues every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6 months for 3 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-d736f9f09f12d6323921
      requested nct id
      NCT01706666
      primary nct id
      NCT01706666
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      74d17d4578106f275a80f8911abfc09a6745c43cf4d5a8f7cdead1dda4f492db
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-d736f9f09f12d6323921
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01706666
      occurrences
      1. context exact
        NCT01706666
        end
        11
        exact text
        NCT01706666
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/171/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      1cfdc8078255dc0549c022fd6693f987122978743be40bb0c530d72dddd67918

    Preserved source evidence · Not medical advice